Compounds > 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone
Page last updated: 2024-09-03

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and sulindac

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with sulindac in 6 studies

Compound Research Comparison

Studies
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)		Trials
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)		Recent Studies (post-2010)
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)		Studies
(sulindac)		Trials
(sulindac)		Recent Studies (post-2010) (sulindac)
25021,462202305

Protein Interaction Comparison

ProteinTaxonomy3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone (IC50)sulindac (IC50)
Aldo-keto reductase family 1 member B10Homo sapiens (human)2.69
Aldo-keto reductase family 1 member B1Homo sapiens (human)2.69
Aldo-keto reductase family 1 member B1Bos taurus (cattle)0.293
Prostaglandin G/H synthase 2Homo sapiens (human)8.8

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's4 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dinchuk, JE; Evans, JF; Hancock, B; Kargman, SL; Kwong, E; Oshima, H; Oshima, M; Taketo, MM; Trzaskos, JM1
Taketo, MM1
Ash, C; Evans, JF; Gallinger, S; Hancock, B; Hay, K; Kargman, S; Kwong, E; Lal, G; Mak, T; Redston, M1
Cheng, ZJ; Finckenberg, P; Louhelainen, M; Merasto, S; Mervaala, EM; Tikkanen, I; Vapaatalo, H1
Arnesen, H; Falk, E; Kontny, F; Kwong, E; Lyngdorf, L; Meztli, A; Olesen, M; Seljeflot, I1
Arber, N; Birkenfeld, S; Bulvik, B; Dvory-Sobol, H; Kazanov, D; Leshno, M; Liberman, E; Luk, P1

Other Studies

6 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and sulindac

ArticleYear
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
    Cell, 1996, Nov-29, Volume: 87, Issue:5

    Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Extracellular Space; Female; Furans; Gene Dosage; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, APC; Intestinal Mucosa; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutagenesis; Prostaglandin-Endoperoxide Synthases; Sulindac; Time Factors

1996
COX-2 and colon cancer.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1998, Volume: 47 Suppl 2

    Topics: Adenomatous Polyposis Coli; Animals; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Furans; Humans; Isoenzymes; Membrane Proteins; Mice; Mice, Knockout; Prostaglandin-Endoperoxide Synthases; Stromal Cells; Sulindac

1998
Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Cancer research, 2001, Aug-15, Volume: 61, Issue:16

    Topics: Adenoma; Animals; Colorectal Neoplasms; Crosses, Genetic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA Repair; DNA-Binding Proteins; Female; Furans; Genes, APC; Intestinal Polyps; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; MutS Homolog 2 Protein; Precancerous Conditions; Prostaglandin-Endoperoxide Synthases; Proto-Oncogene Proteins; Substrate Specificity; Sulindac

2001
Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).
    European journal of pharmacology, 2003, Feb-14, Volume: 461, Issue:2-3

    Topics: Albuminuria; Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Cardiovascular System; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Eating; Furans; Gene Expression Regulation, Enzymologic; Isoenzymes; Kidney; Losartan; Male; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Sulindac; Urination

2003
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice.
    Scandinavian cardiovascular journal : SCJ, 2002, Volume: 36, Issue:6

    Topics: Algorithms; Analysis of Variance; Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cyclooxygenase Inhibitors; Disease Models, Animal; Furans; Male; Mice; Mice, Inbred C57BL; Sulindac

2002
MF tricyclic and sulindac retard tumor formation in an animal model.
    International journal of cancer, 2006, Jan-01, Volume: 118, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Furans; Injections, Subcutaneous; Liver Neoplasms; Mice; Mice, Nude; Placebos; Random Allocation; Single-Blind Method; Sulindac

2006